VALN|Valneva SE|Price:5.680|Chg%:-0.26

More Details of Valneva SE Company

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Valneva SE Info



Ticker SymbolVALN

Company nameValneva SE

IPO dateJun 28, 2007

CEOLingelbach (Thomas)

Number of employees- -

Security typeDepository Receipt

Fiscal year-endJun 28

Address6, Rue Alain Bombard

CitySAINT-HERBLAIN

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryFrance

Postal code44800

Phone33228073710

Websitehttps://valneva.com/

Ticker SymbolVALN

IPO dateJun 28, 2007

CEOLingelbach (Thomas)

Company Executives of Valneva SE



Name

Name/Position

Position

Shareholding

Change

Mr. Franck Grimaud

Chief Business Officer

--

Mr. James R. Sulat

Independent Vice Chairman of the Board

--

Mr. Thomas Lingelbach

President, Chief Executive Officer, Director

--

Ms. Anne-Marie Graffin

Independent Chairman of the Board

--

Dr. Juan Carlos Jaramillo

Chief Medical Officer

--

Mr. Vincent Dequenne

Chief Operating Officer

--

Mr. Peter Buehler

Chief Financial Officer

--

Ms. Dipal Patel

Chief Commercial Officer

--

Mr. James Connolly

Independent Director

--

Ms. Mailys Ferrere

Director, Representative of Bpifrance Participations SA

--

Name

Name/Position

Position

Shareholding

Change

Mr. Franck Grimaud

Chief Business Officer

--

Mr. James R. Sulat

Independent Vice Chairman of the Board

--

Mr. Thomas Lingelbach

President, Chief Executive Officer, Director

--

Ms. Anne-Marie Graffin

Independent Chairman of the Board

--

Dr. Juan Carlos Jaramillo

Chief Medical Officer

--

Mr. Vincent Dequenne

Chief Operating Officer

--

Revenue Breakdown

Currency: USDUpdated: Mon, Apr 6

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

IXIARO

98.42M

56.35%

DUKORAL

31.91M

18.27%

Third party products

19.16M

10.97%

R&D

9.98M

5.72%

IXCHIQ

8.42M

4.82%

Other

6.77M

3.87%

By RegionUSD

Name

Revenue

Proportion

United States

53.61M

30.69%

Canada

30.13M

17.25%

Germany

17.47M

10.00%

France

14.67M

8.40%

Nordics

13.90M

7.96%

Other

44.89M

25.70%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

IXIARO

98.42M

56.35%

DUKORAL

31.91M

18.27%

Third party products

19.16M

10.97%

R&D

9.98M

5.72%

IXCHIQ

8.42M

4.82%

Other

6.77M

3.87%

Shareholding Stats

Updated: Thu, May 7

Shareholders

Shareholder Types

Shareholders

Proportion

Novo Holdings A/S

2.43%

Frazier Life Sciences Management, L.P.

2.42%

General American Investors Company, Inc.

0.37%

Wells Fargo Advisors

0.08%

Morgan Stanley & Co. International Plc

0.03%

Other

94.66%

Shareholders

Proportion

Novo Holdings A/S

2.43%

Frazier Life Sciences Management, L.P.

2.42%

General American Investors Company, Inc.

0.37%

Wells Fargo Advisors

0.08%

Morgan Stanley & Co. International Plc

0.03%

Other

94.66%

Shareholder Types

Shareholders

Proportion

Venture Capital

2.44%

Private Equity

2.42%

Investment Advisor

0.43%

Research Firm

0.17%

Hedge Fund

0.02%

Other

94.51%

Institutional Shareholding



Updated: Wed, Apr 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2026Q1

36

5.21M

5.50%

-309.16K

2025Q4

32

5.27M

6.14%

+505.55K

2025Q3

30

4.53M

5.58%

+3.61M

2025Q2

25

665.50K

0.82%

-300.83K

2025Q1

28

666.20K

0.82%

-333.59K

2024Q4

27

820.97K

1.18%

-47.15K

2024Q3

26

836.06K

1.21%

+31.78K

2024Q2

28

742.08K

1.07%

+162.52K

2024Q1

32

513.10K

0.74%

-47.53K

2023Q4

30

421.64K

0.61%

-110.65K

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Novo Holdings A/S

2.31M

2.66%

-40.00K

-1.71%

Dec 31, 2025

Frazier Life Sciences Management, L.P.

2.29M

2.64%

--

Dec 31, 2025

General American Investors Company, Inc.

354.36K

0.41%

--

Dec 31, 2025

Wells Fargo Advisors

123.46K

0.14%

-30.53K

-19.82%

Dec 31, 2025

Morgan Stanley & Co. International Plc

32.26K

0.04%

+9.49K

+41.70%

Dec 31, 2025

Ironwood Investment Management, LLC

25.14K

0.03%

--

Dec 31, 2025

Citadel Advisors LLC

23.49K

0.03%

+7.08K

+43.17%

Dec 31, 2025

Morgan Stanley Smith Barney LLC

10.70K

0.01%

+500.00

+4.90%

Dec 31, 2025

XTX Markets LLC

10.63K

0.01%

+10.63K

--

Dec 31, 2025

Related ETFs



Name

Proportion

No Data

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data